NCT02874846View on ClinicalTrials.gov

Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Ocular HypertensionOpen Angle Glaucoma
Interventions
DRUG

Netarsudil ophthalmic solution 0.02%

Once daily in both eyes (OU) in the evening (PM) for 7 days

OTHER

Netarsudil Ophthalmic Solution Vehicle

Once daily in both eyes (OU) in the evening (PM) for 7 days

Trial Locations (1)

07921

Nancy Ramirez, Bedminster

Sponsors
All Listed Sponsors
lead

Aerie Pharmaceuticals

INDUSTRY

NCT02874846 - Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution | Biotech Hunter | Biotech Hunter